SequelSEC

Organon & Co. OGN

Pharmaceutical Preparations · CIK 0001821825 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$6.22B
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
$538.00M
Fiscal year ended 2025-12-31

Organon & Co. (OGN) reported revenue of $6.22B and net income of $187.00M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Organon & Co.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Organon & Co. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$6.22B$6.40B$6.26B$6.17B$6.30B$6.53B$7.78B
Cost of revenue$2.90B$2.69B$2.52B$2.29B$2.38B$2.12B$2.27B
Gross profit$3.31B$3.72B$3.75B$3.88B$3.92B$4.41B$5.50B
Operating incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net income$187.00M$864.00M$1.02B$917.00M$1.35B$2.16B$3.22B
Research & developmentUnavailableUnavailableUnavailableUnavailable$443.00M$210.00M$220.00M
Weighted-average diluted sharesshares 260.76Mshares 259.15Mshares 256.27Mshares 255.17Mshares 254.19Mshares 253.52Mshares 253.52M
Pretax income$425.00M$807.00M$673.00M$1.12B$1.53B$2.75B$3.70B
Income tax expense$238.00M-$57.00M-$350.00M$205.00M$178.00M$496.00M$390.00M
Diluted EPS$0.72$3.33$3.99$3.59$5.31$8.52$12.69
Selling, general & administrative$1.72B$1.76B$1.89B$1.70B$1.67B$1.36B$1.44B
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Organon & Co. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$574.00M$675.00M$693.00M$706.00M$737.00M$12.00MUnavailable
Total assets$12.87B$13.10B$12.06B$10.96B$10.68B$10.11BUnavailable
Current assets$4.35B$4.35B$4.51B$3.93B$3.76B$3.57BUnavailable
Total liabilities$12.12B$12.63B$12.13B$11.85BUnavailableUnavailableUnavailable
Current liabilities$2.39B$2.72B$2.92B$2.51B$2.60B$2.67BUnavailable
Total equity incl. NCI$752.00M$472.00M-$70.00M-$892.00M-$1.51B$5.49B$7.04B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$1.41B$1.32B$1.32B$1.00B$915.00M$913.00MUnavailable
Accounts receivable$1.33B$1.36B$1.74B$1.48B$1.38B$1.04BUnavailable
Goodwill$4.15B$4.68B$4.60B$4.60B$4.60B$4.60BUnavailable
Long-term debt$8.63B$8.86B$8.75B$8.90B$9.12B$0Unavailable
Accounts payable$952.00M$1.15B$1.31B$1.13B$1.38B$259.00MUnavailable

Cash flow

Organon & Co. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow$700.00M$939.00M$799.00M$858.00MUnavailableUnavailableUnavailable
Capital expenditures$162.00M$175.00M$251.00M$196.00M$192.00M$255.00M$92.00M
Investing cash flow-$390.00M-$513.00M-$260.00M-$420.00MUnavailableUnavailableUnavailable
Financing cash flow-$561.00M-$368.00M-$569.00M-$433.00MUnavailableUnavailableUnavailable
Net change in cash-$101.00M-$18.00M-$13.00M-$31.00M$667.00M-$249.00M$75.00M
Stock-based compensation$77.00M$105.00M$101.00M$75.00M$59.00M$40.00M$41.00M
Common dividends paid$88.00M$297.00M$294.00M$290.00M$145.00M$0$0
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Organon & Co. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow$538.00M$764.00M$548.00M$662.00MUnavailableUnavailableUnavailable
Gross margin53.3%58.0%59.8%62.8%62.2%67.6%70.8%
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF margin8.7%11.9%8.7%10.7%UnavailableUnavailableUnavailable
SBC / revenue1.2%1.6%1.6%1.2%0.9%0.6%0.5%
Current ratio1.82x1.60x1.54x1.56x1.45x1.33xUnavailable
Revenue YoY growth-2.9%2.2%1.4%-2.1%-3.5%-16.0%Unavailable
Net margin3.0%13.5%16.3%14.9%21.4%33.1%41.4%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable2.8%
CapEx / revenue2.6%2.7%4.0%3.2%3.0%3.9%1.2%
Long-term debt / equity11.47xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate56.0%-7.1%-52.0%18.3%11.6%18.0%10.6%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OGN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-K/A · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.